Lercanidipine Accord (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels on arterial smooth‑muscle cells. This blockade reduces calcium entry, causing the muscles to relax, leading to vasodilation and a decrease in peripheral resistance. The resulting effect is a reduction in systemic blood pressure without significant impact on heart contractility.

The appropriate dose of Lercanidipine Accord is determined by the prescribing healthcare professional based on the patient’s clinical condition, blood‑pressure response, and any concomitant medications. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lercanidipine belongs to the dihydropyridine calcium‑channel blocker class, offering potent vasodilation with a relatively low incidence of reflex tachycardia compared with older agents. Compared with ACE inhibitors or ARBs, it primarily reduces peripheral resistance rather than affecting the renin‑angiotensin system, making it a useful alternative or add‑on therapy in patients who cannot tolerate those classes.

Lercanidipine Accord tablets should be stored at room temperature, below 25 °C, in their original blister or bottle. Keep the product away from moisture, direct sunlight, and excessive heat. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Lercanidipine Accord is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

Serious risks, though uncommon, include severe hypotension, myocardial infarction, cardiac arrhythmias, hepatic dysfunction, and allergic reactions such as angio‑edema or anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like fainting, chest pain, rapid heartbeat, jaundice, or swelling of the face and throat.

Lercanidipine should be avoided in individuals with known hypersensitivity to lercanidipine or any component of the formulation. Caution is advised for patients with severe aortic stenosis, unstable angina, or recent myocardial infarction, and it is contraindicated in those taking strong CYP3A4 inhibitors without medical supervision.